Compare · NVO vs QTTB
NVO vs QTTB
Side-by-side comparison of Novo Nordisk A/S (NVO) and Q32 Bio Inc. (QTTB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and QTTB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 873.1x QTTB ($255.2M).
- Over the past year, NVO is down 21.8% and QTTB is up 590.4% - QTTB leads by 612.2 points.
- QTTB has been more active in the news (14 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 13 for QTTB).
- Company
- Novo Nordisk A/S
- Q32 Bio Inc.
- Price
- -
- -
- Market cap
- $222.81B
- $255.2M
- 1M return
- +15.47%
- +18.91%
- 1Y return
- -21.78%
- +590.41%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 5
- 14
- Recent ratings
- 25
- 13
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest QTTB
- SEC Form S-3 filed by Q32 Bio Inc.
- SEC Form 8-K filed by Q32 Bio Inc.
- SEC Form 424B5 filed by Q32 Bio Inc.
- Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
- SEC Form EFFECT filed by Q32 Bio Inc.
- SEC Form 424B5 filed by Q32 Bio Inc.
- Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- SEC Form 8-K filed by Q32 Bio Inc.
- SEC Form 8-K filed by Q32 Bio Inc.
- Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata